Biography for John Carroll
John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered genomics, biotechnology, healthcare and other business topics for Managed Care, American Banker, Small Times, and Local Business.com, He has also contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and other leading publications. He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. He enjoys hiking, traveling and spending time with his family. Carroll is based in Vermont and Texas and can be reached at email@example.com. Follow @JohnCFierce on Twitter.
Articles by John Carroll
Regado Biosciences earned a pop in its stock price this morning after it put out word that the FDA has granted fast-track status to its anticoagulant REG1. The Basking Ridge, NJ-based biotech's share price is up more than 20% on Monday morning.
A little biotech startup with an impressive lineup of biotech veterans among its backers has won over pharma giant Johnson & Johnson as an early partner on its plan to develop a new drug for Alzheimer's, currently one of the toughest targets in the drug business.
Northwest Biotherapeutics announced that German health regulators have OK'd a special hospital exemption that allows the sale of its controversial--and unproven--dendritic vaccine for brain cancer for all glioma brain cancers.
Some of the leaders in the frenzied late-stage race to develop a PCSK9 drug watched their stock prices stumble on Friday afternoon as word of the FDA's concern about potential neurocognitive side effects in the cholesterol drug class ripped through Twitter.
Peter Thiel's Founders Fund has rarely invested in biotech, looking for more consumer-related plays that help people navigate a turbulent landscape for healthcare.
One of the signal achievements for the biotech industry in the Affordable Care Act was a provision granting 12 years of market exclusivity to biologics. The decade-plus period of protection against generic competition ensured that biologics would remain center stage in the R&D world, especially as Big Pharma tumbled over the patent cliff as it tried to rethink its megablockbuster-sized budgets for drug development.
Now that it's steered its way successfully through the treacherous waters of a Phase II/III study for a new-and-improved drug for Parkinson's, Adamas Pharmaceuticals believes this is the right time to mount a $69 million IPO bid as it sets the stage for a pivotal trial.
Gene editing pioneer Carl June at the University of Pennsylvania is back in the headlines. The academic investigator--heralded for his work on a gene editing technique now being tested for cancer--led a team of scientists who successfully used zinc finger nuclease (ZFN) technology from Sangamo to tailor their T cells, essentially locking a back door used by the lethal virus.
The FDA has rejected one of Eli Lilly's top drug prospects partnered with Boehringer Ingelheim, saying that its SGLT2 drug empagliflozin could not be approved for marketing before Boehringer fixed "deficiencies" at one of its manufacturing facilities.
The last 24 hours offered an important lesson over just how closely analysts and investors are tracking every movement on the immunotherapy front in cancer R&D.